BRPI0014142B8 - composição de vacina comprimida estável, e, pacote para vacinação - Google Patents

composição de vacina comprimida estável, e, pacote para vacinação

Info

Publication number
BRPI0014142B8
BRPI0014142B8 BRPI0014142A BR0014142A BRPI0014142B8 BR PI0014142 B8 BRPI0014142 B8 BR PI0014142B8 BR PI0014142 A BRPI0014142 A BR PI0014142A BR 0014142 A BR0014142 A BR 0014142A BR PI0014142 B8 BRPI0014142 B8 BR PI0014142B8
Authority
BR
Brazil
Prior art keywords
vaccine composition
package
vaccine
vaccination
stable compressed
Prior art date
Application number
BRPI0014142A
Other languages
English (en)
Other versions
BR0014142A (pt
BRPI0014142B1 (pt
Inventor
Gallili Gilad
Frydman Norbert
Original Assignee
Abic Biological Laboratories Ltd
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abic Biological Laboratories Ltd, Teva Pharma filed Critical Abic Biological Laboratories Ltd
Publication of BR0014142A publication Critical patent/BR0014142A/pt
Publication of BRPI0014142B1 publication Critical patent/BRPI0014142B1/pt
Publication of BRPI0014142B8 publication Critical patent/BRPI0014142B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

"composição de vacina e método de empregar a mesma". a presente invenção refere-se a uma composição de vacina em comprimidos duros ou comprimida, compactada estável compreendendo pelo menos um componente antigênico seco por congelamento e um auxiliar de dissolução. é também fornecido um método para facilitar a imunização de um indivíduo contra uma doença compreendendo as etapas de primeiramente dissolver a composição de vacina em comprimidos duros ou comprimida, compactada em uma embalagem com um diluente para formar uma solução de vacina, e administrar a solução de vacina resultante em uma quantidade eficaz para imunização.
BRPI0014142A 1999-08-24 2000-08-21 composição de vacina comprimida estável, e, pacote para vacinação BRPI0014142B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15051499P 1999-08-24 1999-08-24
PCT/US2000/022929 WO2001013896A1 (en) 1999-08-24 2000-08-21 A vaccine composition and method of using the same

Publications (3)

Publication Number Publication Date
BR0014142A BR0014142A (pt) 2002-07-02
BRPI0014142B1 BRPI0014142B1 (pt) 2016-09-27
BRPI0014142B8 true BRPI0014142B8 (pt) 2021-05-25

Family

ID=22534899

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0014142A BRPI0014142B8 (pt) 1999-08-24 2000-08-21 composição de vacina comprimida estável, e, pacote para vacinação

Country Status (21)

Country Link
US (1) US6541001B1 (pt)
EP (1) EP1212045B1 (pt)
JP (1) JP5209160B2 (pt)
CN (1) CN100406004C (pt)
AU (1) AU779403B2 (pt)
BR (1) BRPI0014142B8 (pt)
CA (1) CA2382652A1 (pt)
CY (1) CY1118521T1 (pt)
DK (1) DK1212045T3 (pt)
ES (1) ES2605109T3 (pt)
HK (1) HK1047696A1 (pt)
HU (1) HUP0202537A3 (pt)
IL (2) IL148247A0 (pt)
LT (1) LT1212045T (pt)
MX (1) MXPA02001891A (pt)
PL (1) PL364983A1 (pt)
PT (1) PT1212045T (pt)
RU (1) RU2277905C2 (pt)
TR (1) TR200200477T2 (pt)
WO (1) WO2001013896A1 (pt)
ZA (1) ZA200201816B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
US7923023B2 (en) * 2002-02-25 2011-04-12 Astech International LLC Method and composition for delivery of medicants to animals
US20070248569A1 (en) * 2003-01-07 2007-10-25 Michal Eisenbach-Schwartz Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CA2516291C (en) * 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
WO2005061088A1 (en) * 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
JP2006143594A (ja) * 2004-11-16 2006-06-08 Shionogi & Co Ltd 注射錠
EP1973406B1 (en) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form
WO2007084247A2 (en) * 2005-12-28 2007-07-26 Alza Corporation Stable therapeutic formulations
DE102006054260A1 (de) * 2006-02-28 2007-09-27 Lohmann Animal Health Gmbh & Co. Kg Wasser stabilisierende Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
JP4935761B2 (ja) * 2008-06-02 2012-05-23 株式会社微生物化学研究所 家禽大腸菌症ワクチン
CN106987525B (zh) 2009-05-26 2020-10-27 先进生物营养公司 包含生物活性微生物和/或生物活性材料的稳定干粉组合物及其制造方法
SG182317A1 (en) 2010-01-28 2012-08-30 Advanced Bionutrition Corp Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
KR102023207B1 (ko) 2010-12-02 2019-11-25 온콜리틱스 바이오테크 인코포레이티드 동결건조 바이러스 제형
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
JP6229188B2 (ja) * 2012-03-23 2017-11-15 アドバンスド バイオニュートリション コープ. 生体材料のための安定化組成物
TWI745278B (zh) 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物
RU2712278C2 (ru) 2014-12-22 2020-01-28 Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. Система и способ вакцинации птиц
WO2017019273A1 (en) 2015-07-29 2017-02-02 Advanced Bionutrition Corporation Stable dry probiotic compositions for special dietary uses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929377A (en) 1961-02-09 1963-06-19 Carl Peter Varnet Foot and mouth disease implantation preparations
US3317393A (en) 1964-06-08 1967-05-02 Robert M Chanock Immunization by selective infection of the intestinal tract with an encapsulated live virus
US3458621A (en) * 1966-08-31 1969-07-29 American Home Prod Tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US3603030A (en) 1969-08-29 1971-09-07 Remco Ind Inc Jumping toy
FR2082760A5 (en) 1970-03-26 1971-12-10 France Etat Aerosol immunisation appts - for freeze-dried vaccines
DD106660A1 (pt) 1972-04-10 1974-06-20
US3893280A (en) 1972-06-21 1975-07-08 Burns Biotec Lab Inc Transfer packaging for biologicals
DE2237783A1 (de) 1972-08-01 1974-02-14 Bayern Freistaat Impfstoffzubereitung zur oralen pocken-impfung
DD117250A1 (pt) 1974-11-20 1976-01-05
BE853923A (fr) 1977-04-25 1977-10-25 Rit Rech Ind Therapeut Nouveau vaccin vivant ameliore contre le pseudopeste aviaire et son procede de preparation
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4251509A (en) 1980-01-31 1981-02-17 Wisconsin Alumni Research Foundation Dry particulate vaccine for oral administration
US4458630A (en) 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS63264518A (ja) * 1987-04-21 1988-11-01 Wakamoto Pharmaceut Co Ltd 発泡性錠剤の製法
IL86180A (en) 1987-05-04 1992-08-18 Merck & Co Inc Stable lyophilized live herpes virus vaccine and such a vaccine combined with other virus vaccines
US5710014A (en) 1988-02-11 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Cloned cDNA for human procathepsin l.
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
IL89899A (en) 1988-05-16 1992-12-01 Reynolds Tobacco Co R Smoking article with improved means for delivering flavorants
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JP3412694B2 (ja) 1989-10-02 2003-06-03 シーマ・ラブス、インコーポレイテッド 発泡性投与剤
JP3078013B2 (ja) * 1989-10-02 2000-08-21 エンブレックス インコーポレイテッド ワクチン接合体の使用方法、ワクチン調整物および製造品
ES2102368T3 (es) 1989-10-02 1997-08-01 Univ Arkansas Conjugado de vacuna para el tratamiento de las enfermedades de las aves.
DD289200A5 (de) 1989-11-28 1991-04-25 Forsch Lungenkrankheiten Und T Verfahren zur herstellung einer kombinationsvakzine mit intensivierter wirkung
DD289201A5 (de) 1989-11-28 1991-04-25 Fi Fuer Lungenkrankheiten Und Tuberkulose,De Verfahren zur herstellung einer immunmodulierenden vakzine gegen viren
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
FR2662942B1 (fr) * 1990-06-06 1992-09-18 Neway Tsehay Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
NZ286242A (en) 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
WO1994001533A1 (en) * 1992-07-06 1994-01-20 President And Fellows Of Harvard College Deletion mutants as vaccines for cholera
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
WO1995008562A1 (en) * 1993-09-20 1995-03-30 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) * 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU2520397A (en) * 1996-04-22 1997-11-12 Peter R. Rothschild Stabilized antihepatitis-b vaccine tablets
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
AU4133397A (en) * 1996-10-28 1998-05-22 Pfizer Inc. Oral vaccines for young animals with an enteric coating
US6150340A (en) * 1997-02-07 2000-11-21 Smithkline Beecham Corporation RNA-dependent amidotransferase from Staphylococcus aureus
JPH1121122A (ja) * 1997-07-03 1999-01-26 Akou Kaisui Kk 水溶解性に優れた塩錠剤
DE19741114C2 (de) 1997-09-12 2002-10-24 Riemser Arzneimittel Ag Feuchtigkeitsstabile und magensaftresistente Arzneiform für Fische
CU22700A1 (es) 1997-09-29 2001-07-31 Ct Ingenieria Genetica Biotech Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
GB9722682D0 (en) 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
GB9801870D0 (en) 1998-01-28 1998-03-25 Raby Limited Vaccine composition
AU2997500A (en) 1999-02-16 2000-09-04 Prismedical Corporation Single dose delivery device

Also Published As

Publication number Publication date
IL148247A0 (en) 2002-09-12
WO2001013896A1 (en) 2001-03-01
TR200200477T2 (tr) 2002-06-21
CN1379663A (zh) 2002-11-13
CN100406004C (zh) 2008-07-30
JP5209160B2 (ja) 2013-06-12
DK1212045T3 (en) 2016-11-28
BR0014142A (pt) 2002-07-02
PL364983A1 (en) 2004-12-27
AU779403B2 (en) 2005-01-20
MXPA02001891A (es) 2003-07-21
HUP0202537A2 (hu) 2002-11-28
PT1212045T (pt) 2016-11-22
IL148247A (en) 2014-01-30
EP1212045A4 (en) 2008-02-20
CA2382652A1 (en) 2001-03-01
EP1212045A1 (en) 2002-06-12
JP2003507414A (ja) 2003-02-25
RU2277905C2 (ru) 2006-06-20
BRPI0014142B1 (pt) 2016-09-27
ES2605109T3 (es) 2017-03-13
HUP0202537A3 (en) 2004-05-28
HK1047696A1 (zh) 2003-03-07
CY1118521T1 (el) 2017-07-12
AU6793400A (en) 2001-03-19
US6541001B1 (en) 2003-04-01
EP1212045B1 (en) 2016-08-17
ZA200201816B (en) 2003-05-28
LT1212045T (lt) 2016-12-12

Similar Documents

Publication Publication Date Title
BRPI0014142B8 (pt) composição de vacina comprimida estável, e, pacote para vacinação
ATE463261T1 (de) Meningokokken-konjugat-impfung
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
BRPI0510315A (pt) integração de vacinação com conjugado meningocócico
TR201909267T4 (tr) Sinakalset HCl içeren hızlı çözünme formülasyonu.
UY27366A1 (es) Vacunación en dosis única con mycoplasma hyopneumoniae
HUP0401606A2 (hu) West Nile vakcina
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
EA200500080A1 (ru) Дозированная форма прамипексола, принимаемая один раз в день
WO2002067846A8 (en) A vaccine composition and method of using the same
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
KR910007867A (ko) 페네타놀아민 화합물
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
PE20020903A1 (es) Metodo para prevenir la diarrea
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.
WO2004089969A3 (en) Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
WO2001054718A3 (en) Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
TR200102196T2 (tr) Mono-asiloksi aralkil nöromuskular relaksanları.
ECSP003771A (es) Metodo para prevenir la diarrea

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABIC BIOLOGICAL LABORATORIES LTD. (IL)

Free format text: TRANSFERIDO DE: TEVA PHARMACEUTICAL INDUSTRIES, LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 9/28, A61K 9/30, A61P 31/00

Ipc: A61K 9/28 (2011.01), A61K 9/30 (2011.01), A61P 31/

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/09/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/08/2020